

## ritlecitinib (Litfulo®)

SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2610	For the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	17/04/2024	31/07/2024
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/media/8228/ritlecitinib-litfulo-final-march-2024-for-website.pdf">https://www.scottishmedicines.org.uk/media/8228/ritlecitinib-litfulo-final-march-2024-for-website.pdf</a>				

## daridorexant (Quviviq®)

SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2611	treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.  SMC restriction: in patients who have failed cognitive behavioural therapy for insomnia (CBT-I) or for whom CBT-I is unsuitable or unavailable.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	17/04/2024	31/07/2024
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/media/8230/daridorexant-quviviq-final-march-2024-for-website.pdf">https://www.scottishmedicines.org.uk/media/8230/daridorexant-quviviq-final-march-2024-for-website.pdf</a>				

<b>mavacamten (Camzyos®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date of ADTC</b>	<b>Date of decision / Expected date of decision</b>
SMC2618	treatment of symptomatic (New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	17/04/2024	31/07/2024
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/media/8226/mavacamten-camzyos-final-march-2024-for-website.pdf">https://www.scottishmedicines.org.uk/media/8226/mavacamten-camzyos-final-march-2024-for-website.pdf</a>				
<b>tirzepatide (Mounjaro®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date of ADTC</b>	<b>Date of decision / Expected date of decision</b>
SMC2633	for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: as monotherapy when metformin is considered inappropriate due to intolerance or contraindications in addition to other medicinal products for the treatment of diabetes. SMC restriction: in addition to other oral anti-diabetic medicines as an option when glucagon-like peptide-1 (GLP-1) receptor agonists would be considered.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	17/04/2024	31/07/2024
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/media/8229/tirzepatide-mounjaro-final-march-2024-amended-020424-for-website.pdf">https://www.scottishmedicines.org.uk/media/8229/tirzepatide-mounjaro-final-march-2024-amended-020424-for-website.pdf</a>				

<b>dostarlimab (Jemperli®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date of ADTC</b>	<b>Date of decision / Expected date of decision</b>
SMC2635	in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	17/04/2024	31/07/2024
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/media/8231/dostarlimab-jemperli-final-march-2024-for-website.pdf">https://www.scottishmedicines.org.uk/media/8231/dostarlimab-jemperli-final-march-2024-for-website.pdf</a>				
<b>mirikizumab (Omvoh®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date of ADTC</b>	<b>Date of decision / Expected date of decision</b>
SMC2650	For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.  Mirikizumab offers an additional treatment choice in the therapeutic class of interleukin inhibitors.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	17/04/2024	31/07/2024
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/media/8227/mirikizumab-omvoh-abb-final-march-2024-for-website.pdf">https://www.scottishmedicines.org.uk/media/8227/mirikizumab-omvoh-abb-final-march-2024-for-website.pdf</a>				

glycopyrronium/formoterol fumarate (Bevespi Aerosphere®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2652	<p>as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).</p> <p>Glycopyrronium/formoterol fumarate (Bevespi Aerosphere®) offers an additional treatment choice in the therapeutic class of a long-acting muscarinic antagonist (LAMA) in combination with a long-acting beta2-adrenergic agonist (LABA).</p>	Not routinely available as the ADTC is waiting for further advice from local clinical experts	17/04/2024	31/07/2024
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/media/8232/glycopyrronium-formoterol-fumarate-bevespi-aerosphere-abb-final-march-2024-for-website.pdf">https://www.scottishmedicines.org.uk/media/8232/glycopyrronium-formoterol-fumarate-bevespi-aerosphere-abb-final-march-2024-for-website.pdf</a>				